[Clinical trial of a new topical anti-histamine agent histimet in the treatment of seasonal allergic rhinoconjunctivitis].
21 patients with seasonal allergic rhinoconjunctivitis (SAC) entered the trial of a new topical antihistamine drug histimet (levocabastine). The drug is available as a nasal spray and eye drops. The relief of the main symptoms of SAC occurred 15-20 min after histimet introduction into the nose or eye. The effect of a single procedure lasted for 12 hours. Regression of SAC basic symptoms continued for 7 days after using histimet. A significant improvement of life quality was observed. Good effect achieved in 90% of the patients characterizes histimet as an effective new modality in SAC management.
Bulycheva
N A
NA
Ekinova
G M
GM
Vasil'eva
T G
TG
D000287:Administration, Topical; D000293:Adolescent; D000328:Adult; D003233:Conjunctivitis, Allergic / Q000150:complications / Q000188:drug therapy*; D005260:Female; D006634:Histamine H1 Antagonists / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D006255:Rhinitis, Allergic, Seasonal / Q000150:complications / Q000188:drug therapy*
D006634:Histamine H1 Antagonists
Opyt primeneniia novogo topicheskogo antigistaminnogo preparata gistimet v lechenii sezonnogo allergicheskogo rinokon''iunktivita.